Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Part of paid clinical trials in Burbank, California.
- Sponsor
- National Cancer Institute (NCI)
- Study ID
- NCT01199263
- Phase
- PHASE2
- Status
- Completed
Conditions
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Laboratory Biomarker Analysis — OTHERCorrelative studies
- Paclitaxel — DRUGGiven IV
- Pelareorep — BIOLOGICALGiven IV
Study Details
This randomized phase II trial studies the side effects and how well giving paclitaxel with or without viral therapy works in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal cancer that has come back. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Viral therapy may be able to kill tumor cells without damaging normal cells. Giving paclitaxel together with viral therapy may kill more tumor cells.
Key Dates
- Start date
- Dec 6, 2010
- Status verified
- Aug 2020
- Primary completion
- Jun 1, 2015
- Completion
- Jul 17, 2020
Study Design
- Enrollment
- 108 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm I (paclitaxel)Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
- Experimental: Arm II (paclitaxel and wild-type reovirus)Patients receive paclitaxel as in arm I and wild-type reovirus IV over 1 hour on days 1-5.
Primary Outcome Measure
Progression-free Survival (PFS) [ Time Frame: Approximately 4.5 years. ]
Locations (36)
Find similar trials in Burbank, CA
By research site
Providence Saint Joseph Medical Center/Disney Family Cancer Center· Burbank, CAPalo Alto Medical Foundation-Gynecologic Oncology· Mountain View, CASmilow Cancer Hospital Care Center at Saint Francis· Hartford, CTNortheast Georgia Medical Center-Gainesville· Gainesville, GASaint Alphonsus Cancer Care Center-Boise· Boise, IDIndiana University/Melvin and Bren Simon Cancer Center· Indianapolis, IN
Related Studies
- Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTFPHASE1 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic CancersPHASE1 · Recruiting · M.D. Anderson Cancer Center · Baltimore, Maryland
- ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian CancerPHASE2 · Recruiting · Ira Winer · Detroit, Michigan
- Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By GenomicsPHASE1 · Recruiting · University of Utah · Salt Lake City, Utah